76282-48-9

Basic information

• Product Name: Oxiraneethanol, (2R)-
• CAS NO: 76282-48-9
• Molecular Formula: C4H8O2
• Molecular Weight: 88.1063
• Mol File: 76282-48-9.mol
• Article Data: 34

Chemical Properties

• CAS DataBase Reference: Oxiraneethanol, (2R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Oxiraneethanol, (2R)-(76282-48-9)
• EPA Substance Registry System: Oxiraneethanol, (2R)-(76282-48-9)

Safety Data

• Hazardous Substances Data: 76282-48-9(Hazardous Substances Data)

Usage

General Description

The chemical "Oxiraneethanol, (2R)-" is also known as "R-(-)-glycidol". It is an organic compound with the chemical formula C3H6O2. It belongs to the family of epoxides and is chiral with its purity estimated in terms of its enantiomeric excess. Glycidol is typically used in the synthesis of glycerol, glycidyl ethers, and amines. It's also utilized as a stabilizer for natural oils and vinyl polymers and as a demulsifier. Its applications span across various industries including pharmaceuticals, food processing, and agriculture. It is important to note that it is a potential health hazard and has been listed as possibly carcinogenic by the International Agency for Research on Cancer.

Upstream product

• 97719-35-2 (-)-(S)-2-phenylsulfanylbutane-1,4-diol 
• 97719-36-3 (R)-2-phenylthio-1,4-butanediol 
• 627-27-0 homoalylic alcohol 
• 95337-96-5 (S)-1-bromo-2,4-butanediol 2,4-diacetate 
• 56-84-8 L-Aspartic acid 
• 97678-51-8 (S)-2-p-toluenesulfonyloxy-1,4-butanediol 
• 87018-31-3 (S)-2-bromo-(1,4)-butanediol 
• 101021-55-0 (2S)-chlorobutane-1,4-diol 
• 122169-83-9 5-(d)-menthyloxy-4-phenylthiobutyrolactone 
• 137846-89-0 (R)-2-Bromo-1,4-butanediol 1,4-diacetate 
• 76282-47-8 (S)-1,2,4-butanetriol 1,4-diacetate 2-methanesulfonate 
• 115114-87-9 (2R)-2-(2-benzyloxyethyl)oxirane 
• 101021-57-2 (2R)-2-chlorobutane-1,4-diol 
• 95338-04-8 (2-((S)-oxiran-2-yl)ethoxy)(tert-butyl)dimethylsilane 

Downstream Products

• 91111-12-5 2-(oxiran-2-yl)ethyl 4-methylphenylsulfonate 
• 1452390-84-9 (S)-2-(2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)oxirane 
• 41241-10-5 (R)-<2<(Methanesulfonyl)oxy>ethyl>oxirane 
• 95337-97-6 (R)-2-(2-(tert-butyldimethylsilyloxy)ethyl)oxirane 
• 115114-87-9 (2R)-2-(2-benzyloxyethyl)oxirane 
• 125975-53-3 tert-butyl [2-[(2R)-oxiran-2-yl]ethoxy]diphenylsilane 
• 95338-04-8 (2-((S)-oxiran-2-yl)ethoxy)(tert-butyl)dimethylsilane 
• 1198569-81-1 tetrahydro-2-{2-[(2R)-oxiran-2-yl]ethoxy}-2H-pyran 
• 85960-55-0 (S)-(2-phenylmethoxyethyl)oxirane 
• 111006-14-5 (R)-3,4-epoxybutyric acid 

Relevant articles and documents

Stereoselective synthesis of resorcylic acid lactone Cochliomycin B

The total synthesis of 14-membered resorcylic acid lactone, Cochliomycin B has prescribed, in a convergent manner, from readily available starting materials, D-galactose, L-aspartic acid and ethyl acetoacetate. The key reactions involved in the synthesis are Julia-Kocienski olefination, E-selective Horner-Wadsworth-Emmons olefination and intramolecular lactonization.

Synthesis and Evaluation of Novel TLR2 Agonists as Potential Adjuvants for Cancer Vaccines

Cancer immunotherapy has gained increasing attention due to its potential specificity and lack of adverse side effects when compared to more traditional modes of treatment. Toll-like receptor 2 (TLR2) agonists are lipopeptides possessing the S-[2,3-bis(palmitoyloxy)propyl]-l-cysteine (Pam2Cys) motif and exhibit potent immunostimulatory effects. These agonists offer a means of providing "danger signals" in order to activate the immune system toward tumor antigens. Thus, the development of TLR2 agonists is attractive in the search of potential immunostimulants for cancer. Existing SAR studies of Pam2Cys with TLR2 indicate that the structural requirements for activity are, for the most part, very intolerable. We have investigated the importance of stereochemistry, the effect of N-terminal acylation, and homologation between the two ester functionalities in Pam2Cys-conjugated lipopeptides on TLR2 activity. The R diastereomer is significantly more potent than the S diastereomer and N-terminal modification generally lowers TLR2 activity. Most notably, homologation gives rise to analogues which are comparatively active to the native Pam2Cys containing constructs.

PEPTIDE CONJUGATES, CONJUGATION PROCESS, AND USES THEREOF

The invention relates to peptide conjugates, methods for making peptide conjugates, conjugates produced by the methods, and pharmaceutical compositions comprising the conjugates. Methods of eliciting immune responses in a subject and methods of vaccinating a subject, uses of the conjugates for the same, and uses of the conjugates in the manufacture of medicaments for the same are also contemplated.